Document is current
Any future updates will be listed below
-
Authors
Wang, Yeming
Shang, Lianhan
Wu, Lei
Wang, Xia
Ding, Banghan
Hu, Ke https://orcid.org/0000-0001-9862-7239
He, Yingli
Li, Guangming
Zhai, Jie
Hu, Junyan
Tian, Yingping
Wang, Jun
Yan, Li
Liu, Bin
Song, Gengshen https://orcid.org/0009-0001-3556-7459
He, Yuxian https://orcid.org/0000-0003-2048-6696
Wang, Chen https://orcid.org/0000-0001-7857-5435
-
Funding
Funding for this research was provided by:
National key research and development program of China
- License Information
-
More Information
Article History
Received: 8 May 2025
Accepted: 15 July 2025
First Online: 7 August 2025
Competing interests
: Bin Cao discloses his role as PI in China for the baloxavir transmission trial sponsored by Roche and as PI of GP681 Phase II and Phase III trials sponsored by Qingfeng Pharmaceutical Group Co., Ltd. Yeming Wang serves as the sub-PI. Yeming Wang also discloses receiving compensation as rapporteur for “Optimizing the Clinical Management of Patients” in the 2024 update of the WHO Public Health Research Agenda for Influenza, led by WHO. Gengshen Song and Xia Wang are employees of Youcare Pharmaceutical Co., Ltd. Jie Zhai is an employee of Beijing Yolax Pharmaceutical Technology Co., Ltd. The remaining authors declare no competing interests.
